Details for New Drug Application (NDA): 020605
✉ Email this page to a colleague
The generic ingredient in ZOFRAN is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
Summary for 020605
Tradename: | ZOFRAN |
Applicant: | Sandoz |
Ingredient: | ondansetron hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | EQ 4MG BASE/5ML | ||||
Approval Date: | Jan 24, 1997 | TE: | RLD: | Yes |
Expired US Patents for NDA 020605
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sandoz | ZOFRAN | ondansetron hydrochloride | SOLUTION;ORAL | 020605-001 | Jan 24, 1997 | 4,695,578*PED | ⤷ Subscribe |
Sandoz | ZOFRAN | ondansetron hydrochloride | SOLUTION;ORAL | 020605-001 | Jan 24, 1997 | 5,854,270*PED | ⤷ Subscribe |
Sandoz | ZOFRAN | ondansetron hydrochloride | SOLUTION;ORAL | 020605-001 | Jan 24, 1997 | 4,753,789*PED | ⤷ Subscribe |
Sandoz | ZOFRAN | ondansetron hydrochloride | SOLUTION;ORAL | 020605-001 | Jan 24, 1997 | 5,578,628*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription